Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter Google Plus

San Antonio Breast Cancer Symposium – Targeting HER2 Beyond Herceptin

Day 2 - Continuing Coverage of the 33rd CTRC-AACR SABCS

Join us for complete coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2.

Several papers describing research into the screening and management of breast cancer patients were presented today at the meeting.

Key Late-Breaking Clinical Trials Covered:

• Lapatinib vs Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44)

• Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study (‘NeoSphere’)

• First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

Highlighted in the video is expert commentary from leaders in breast cancer including:

• Michael Untch, MD, PhD, Head, Clinic for Gynecology, Gynecologic Oncology, and Obstetrics, Head, Breast Interdisciplinary Cancer Center, Department of Obstetrics and Gynecology, Academic Hospital of the University of Charité Berlin

• Luca Gianni, MD, Director, Medical Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano

• José Baselga, MD, PhD, Chief, Division of Hematology and Oncology, Associate Director, Massachusetts General Hospital Cancer Center

For more information from SABCS 2010, please click here: SABCS 2010.